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Abstract
Oncolytic virotherapies (OV) based on human adenoviral (HAdV) vectors hold signiﬁcant promise for the treatment of
advanced ovarian cancers where local, intraperitoneal delivery to tumour metastases is feasible, bypassing many
complexities associated with intravascular delivery. The efﬁcacy of HAdV-C5-based OV is hampered by a lack of tumour
selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely,
folate receptor alpha (FRα) is highly expressed on ovarian cancer cells, providing a compelling target for tumour selective
delivery of virotherapies. Here, we identify high-afﬁnity FRα-binding oligopeptides for genetic incorporation into HAdV-C5
vectors. Biopanning identiﬁed a 12-mer linear peptide, DWSSWVYRDPQT, and two 7-mer cysteine-constrained peptides,
CIGNSNTLC and CTVRTSAEC that bound FRα in the context of the phage particle. Synthesised lead peptide,
CTVRTSAEC, bound speciﬁcally to FRα and could be competitively inhibited with folic acid. To assess the capacity of the
elucidated FRα-binding oligopeptides to target OV to FRα, we genetically incorporated the peptides into the HAdV-C5
ﬁber-knob HI loop including in vectors genetically ablated for hCAR interactions. Unfortunately, the recombinant vectors
failed to efﬁciently target transduction via FRα due to defective intracellular trafﬁcking following entry via FRα, indicating
that whilst the peptides identiﬁed may have potential for applications for targeted drug delivery, they require additional
reﬁnement for targeted virotherapy applications.
Introduction
Ovarian cancer is the sixth most common cause of cancer
death in the UK, resulting in over 4000 deaths each year in
the UK and 152,000 deaths worldwide (https://www.ca
ncerresearchuk.org/health-professional/cancer-statistics/sta
tistics-by-cancer-type/ovarian-cancer). Approximately 90%
of ovarian cancers are of epithelial origin, categorised as
serous, mucinous or endometroid [1]. The disease is typi-
cally asymptomatic in the early stages, commonly leading
to late patient presentation and diagnosis and a 5-year
survival rate of 46% [2]. Platinum-based chemotherapies
are the ﬁrst-line treatment; however, patients often develop
chemo-resistance (https://www.cancerresearchuk.org/hea
lth-professional/cancer-statistics/statistics-by-cancer-type/
ovarian-cancer) [2].
The use of adenoviral-based oncolytic virotherapies
holds signiﬁcant promise as anti-cancer agents due to their
ability to self-amplify within tumours, lyse cells inducing
immunogenic cell death, and express therapeutic modalities
encoded within the viral genome. In the context of ovarian
cancer, their deployment clinically is especially appealing
since local delivery to tumour metastases via the intraper-
itoneal route is feasible, bypassing many restrictions that are
associated with delivery via the bloodstream. To date the
efﬁcacy of HAdV-C5, the most commonly used HAdV
vector for cancer gene therapy, has been hampered due to a
lack of selectivity for cancer cells [3–5]. One approach is to
identify ligands for cellular receptors that are unique to or
overexpressed on tumour cells with low or absent expres-
sion in normal tissue. Cancer-targeting peptides have the
potential for targeted drug delivery, enhancing therapeutic
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beneﬁt and minimising off-target toxicities [6]. For vir-
otherapy applications, incorporation of cancer-targeting
peptides into the HI loop of the adenoviral ﬁbre knob, the
capsid protein that interacts with the native adenoviral
receptor coxsackie adenovirus receptor (CAR) for cell
entry, is an opportune targeting strategy for developing
high-afﬁnity, retargeted HAdV vectors [7]. Recently, we
described such an approach to develop a “precision vir-
otherapy” based on targeting the tumour associated integrin,
αvβ6 using a previously identiﬁed, 20-amino-acid αvβ6-
binding peptide, A20. The resultant virotherapy, Ad5NULL-
A20, demonstrated a remarkable ability to purge xeno-
grafted SKOV3 ovarian cancers in an intraperitoneal model
of ovarian cancer [8]. However, αvβ6 is overexpressed in
around 33% of advanced ovarian cancers [9], and therefore
the majority of patients presenting with late-stage ovarian
cancer may not be amenable to precision virotherapies tar-
geted to αvβ6.
Retargeting HAdV vector tropism towards the folate
receptor alpha (FRα) represents an excellent approach for
treating ovarian cancer. The FRα is a glycosylpho-
sphatidylinositol (GPI) anchored membrane protein that
binds and internalises folate for purine and thymidine
DNA biosynthesis, repair and methylation. The FRα
confers a tumour growth advantage and is positively
associated with histological stage and grade and poor
overall survival. In normal tissues, the expression of FRα
is strictly conﬁned to the apical membrane of polarised
epithelial cells and is not usually expressed in normal
ovarian epithelium but expressed in over 70% of primary
and 80% of recurrent ovarian cancers [10]. The folate
receptor represents an attractive target for the development
of folate receptor nanoparticles for cancer detection and
treatment. Such folate nanoconjugates consisting of
polymers, micelles, dendrimers and liposomes, to name
but a few, show promise in the approach of nanoparticle
targeting of folate receptor-positive cancer cells and is
reviewed elsewhere [11]. In the context of viral retargeting
to the folate receptor, a previous study showed that che-
mical conjugation of folate to a murine Moloney leukae-
mia (retrovirus) vector failed to transduce folate receptor-
positive cells. Although the folate-derivatised virus
showed signiﬁcant and speciﬁc binding to cells, the virus
was not efﬁciently internalised, probably due to poor
endocytosis of virus by folate receptors, perhaps incom-
patible with the native tropism of the virus. This suggests
that even tight binding of virus to the cellular membrane
does not always translate to efﬁcient transduction cap-
abilities [12]. Indeed, there is controversy as to whether
the folate receptor pathway is a viable route for nano-
particles and viral vectors. Engineering adenoviral vectors
retargeted to the folate receptor represents an excellent
approach to addressing this question.
Phage display is a selection procedure for elucidating
peptides binding partners to a given target of interest [13–15].
Commercial phage libraries are commonly based on the
ﬁlamentous bacteriophage M13, typically consisting of 1010
randomised peptide sequences expressed as fusions to the
bacteriophage coat protein pIII. Biopanning against whole
cells requires incubating phage library with cells expressing
the target of interest, washing away unbound phage before
speciﬁcally eluting phage bound to the receptor of interest by
competitive inhibition using a known receptor interacting
agonist. Eluted phage is then collected, ampliﬁed and enri-
ched for target-speciﬁc bound phage in subsequent rounds of
bioselection.
The DNA encoding each peptide within the virion is
physically linked to the peptide expressed on the coat pro-
tein allowing rapid elucidation of the DNA sequence of
target-bound peptides. Although a number of pre-clinical
phage display studies show promise for the utility of cancer-
targeting peptides [16, 17], clinical data demonstrate the
need for further optimisation for translational success in
terms of improving receptor afﬁnity, enzyme instability and
pharmacokinetics [18, 19]. A number of clinical trials are
exploring the potential therapeutic opportunities for target-
ing the FRα and are reviewed extensively elsewhere [20].
The monoclonal FRα antibody Farletuzumab (MORAb-
003) shows conﬂicting efﬁcacy data, whilst limited efﬁcacy
was demonstrated in trials evaluating the folate-conjugated
drug Vintafolide (MK-8109, EC145). IMGN853 (Mirve-
tuximab soravtansine), an anti-FRα antibody conjugated to
a cytotoxic drug is currently undergoing Phase I clinical
trials [21]. In contrast to antibody-based agents, small
cancer-targeting peptides have the advantage of their small
size, potentially permitting easy penetration into tissue,
reduced immunogenicity and easy synthesis and scale-up
[18]. Peptides identiﬁed from phage libraries that have been
used for HAdV retargeting to the tumour vasculature
include the RGD-binding cellular integrins [22], NGR
peptide-binding aminopeptidease N (APN) [23] and human
epidermal growth factor (EGFR) GE11 peptide [24].
HAdV-based virotherapies can be readily genetically
modiﬁed to incorporate peptides targeting cancer-restricted
receptors within permissive regions of the adenoviral ﬁbre
knob protein; however, further reﬁnements are often
necessary to overcome limitations in clinical efﬁcacy
associated with off-target uptake [25].
In the present study, we performed whole-cell biopan-
ning of SKOV3 ovarian carcinoma cells using phage dis-
play libraries to identify FRα-speciﬁc peptides and tested
their binding speciﬁcity in vitro. To evaluate the potential to
generate a “precision virotherapy” targeted to FRα, we
genetically incorporated FRα-binding oligopeptides into the
HI loop of the adenoviral ﬁbre knob domain and evaluated
their ability to direct viral tropism towards FRα in vitro.
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Materials and methods
Cell lines
SKOV3 cells (human ovarian adenocarcinoma derived from
ascites) were originally obtained from the American Type
Culture Collection (ATCC). Cells were cultured and
maintained in Dulbecco's Modiﬁed Eagle's medium
(DMEM) supplemented with 10% foetal calf serum (FCS),
2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL
streptomycin. Cells were maintained at 37 °C and 5% CO2.
All reagents were purchased from Gibco or Thermo Sci-
entiﬁc (Paisley, UK). Cells were routinely tested for
mycoplasma (every 3–6 months).
Flow cytometric analysis of receptors expressed on
SKOV3 cells
SKOV3 cells were seeded at a density of 1.5 × 105 cells per
well in a 96-well plate. Cells were washed in 200 µL of
wash buffer (PBS/1% BSA) and incubated with 100 µL of
wash buffer containing 1:500 of mouse anti-human mono-
clonal antibody against CAR (RmcB, Millipore, Watford,
UK), 1:50 of mouse anti-human monoclonal anti-folate
binding protein antibody (clone EPR4708(2)) (Abcam, UK)
or mouse IgG control antibody (Santa Cruz Biotechnology,
Heidelberg, Germany) for 1 h on ice. Cells were washed
three times and incubated with a 1:500 dilution of goat anti-
mouse Alexa Fluor 647 antibody (Invitrogen, UK) for
30 min on ice. Cells were ﬁxed in 4% paraformaldehyde for
20 min at 4 °C. A total of 2 × 104 gated events were
acquired in channel FL-4 on a BD Accuri C6 (BD Bios-
ciences, USA) ﬂow cytometer and data analysed in BD
Accuri C6 software version 1.0.264.21 (Becton Dickinson,
USA). CAR and FR binding was analysed by ﬂow cyto-
metry relative to IgG isotype binding.
Phage libraries
The Ph.D.−12, Ph.D.−7 and Ph.D.−C7C Phage Display
Peptide Libraries were purchased from New England Biolabs
(UK). The combinatorial library of random dodecapeptides
(Ph.D.−12) and heptapeptides (Ph.D.−7 and Ph.D.−C7C)
are fused to a minor coat protein (pIII) of M13 phage. The
displayed peptides (12-mer and 7-mer, respectively) are
expressed at the N-terminus of pIII. The library consists of
1 × 1013 plaque forming units (pfu)/mL phage with 109 ran-
dom sequences yielding ~100 copies of each sequence.
Phage biopanning
SKOV3 cells were seeded at 5 × 105 cells per well in a 6-
well plate in DMEM, 10% FCS and cultured at 37 °C, 5%
CO2. After 24 h, cells were cooled to 4 °C for 30 min. Cells
were washed twice with cold PBS. Phage library was added
at 2 × 1011 phage particles in a total volume of 1 mL
DMEM/1% BSA and incubated with gentle rocking at 4 °C
for 1 h. Unbound phage was removed (and stored at 4 °C).
Cells were washed four times for 2 min in PBS/1% BSA.
Bound phages were eluted by addition of 1 mL of folic acid
(Acros organics, Fisher Scientiﬁc, UK) in PBS (100 µg/mL)
by competitive inhibition for 1 h at 4 °C. Phages were stored
at 4 °C until analysis (unampliﬁed eluate). Unampliﬁed
eluted phage was titred to determine the success of each
round of biopanning.
Phage titering
A single ER2738 bacterial colony was cultured in Luria
Bertani (LB) broth overnight with tetracycline at 37 °C,
150 rpm. Tenfold serial dilutions of unampliﬁed phage
(101–104) in LB were prepared overnight and added to
overnight ER2738 cultures. After immediate and brief vor-
texing, diluted phage was incubated at room temperature for
1–5min and transferred to a tube containing 3mL of 4 °C
agarose top. After a brief vortex, bacterial cultures were
poured onto pre-warmed LB/IPTG/Xgal plates, cooled for
5 min and incubated overnight at 37 °C. The next day, plaques
were counted to calculate number of plaque forming units.
Phage ampliﬁcation
A single ER2738 bacterial colony was cultured in LB broth
overnight with tetracycline at 37 °C, 150 rpm; 3 mL of
overnight culture was added to 20 mL of LB and unam-
pliﬁed eluate added. Phages were ampliﬁed at 37 °C,
150 rpm. The culture was centrifuged at 10,000 rpm
(12,000×g) for 20 min at 4 °C. The supernatant was trans-
ferred to a fresh tube and centrifuged. The upper 80%
(~19 mL) of the supernatant was transferred to a fresh tube
and 1/6th volume (~3 mL) of PEG/NaCl added. Phages
were precipitated at 4 °C overnight.
PEG precipitation
The PEG precipitate was centrifuged at 10,000 rpm for
15 min at 4 °C. The supernatant was discarded and re-
centrifuged brieﬂy to remove residual supernatant. The
phage pellet was resuspended in 1 mL of TBS and cen-
trifuged in a clean tube at 13,000 rpm, for 5 min at 4 °C. The
supernatant was transferred to a clean tube, precipitated with
1/6th volume (~166 µL) of PEG/NaCl, incubated on ice for
30 min followed by centrifugation at 13,000 rpm for 10 min
at 4 °C. The supernatant was discarded and centrifuged
brieﬂy to remove residual supernatant. The pellet was
resuspended in 200 µL of TBS, 0.025 NaN3 and centrifuged
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for 1 min to pellet residual insoluble material. The super-
natant was transferred to a clean tube as the ampliﬁed eluate.
The ampliﬁed eluate was titred as described above using
108–1011 dilutions of ampliﬁed phage eluate.
Plaque ampliﬁcation and puriﬁcation
Unampliﬁed eluate was titred as described above. Plates were
incubated at 37 °C for no longer than 18 h. Plaques (blue)
were picked using a sterile pipette tip and incubated for 2 h at
room temperature. Using overnight ER2738 cultures in LB, a
1:100 dilution (30 µL) was added to 3 mL of LB. Cultures
were incubated at 37 °C overnight (without shaking). A total
of 1.5 mL of culture was analysed for sequencing by cen-
trifugation at 14,000 rpm for 10min; 500 µL of phage-
containing supernatant was transferred to a fresh tube, the
remaining 1 mL re-centrifuged and the upper 80% of the
supernatant transferred to a fresh tube (ampliﬁed phage
stock). A total of 500 µL of phage-containing supernatant
was added to 200 µL of PEG/NaCl, inverted to mix and
incubated for 10min at room temperature. Phage was cen-
trifuged at 14,000 rpm for 10min at 4 °C. The supernatant
was discarded and pellet resuspended in 100 µL of iodide
buffer with vigorous tapping of the tube; 250 µL of ethanol
was added, incubated for 10min at room temperature and
centrifuged at 14,000 rpm for 10min at 4 °C. The supernatant
was discarded and the pellet washed with 70% ethanol, dried
brieﬂy at 37 °C and pellet resuspended in Tris/EDTA. A total
of 5 µL was used for direct sequencing.
Peptide synthesis
TVRTSAE incorporating a thiol group (TVRTSAEGGCGG)
was synthesised by ArchieChem (UK) and conjugated to
Alexa Fluor 647 C2 maleimide (Thermo Fisher, UK).
TVRTSAE labelled with FITC (TVRTSAEGGCGG-COOH)
was commercially synthesised by Innovagen (Lund, Sweden),
converted to acetate salt for use on live cells. Peptide purity
and mass was determined by HPLC and ESI-MS, respectively.
Phage cell-binding assay
SKOV3 cells were seeded in 8-well Nunc Lab-TekTM II
chamber slides (Thermo-Scientiﬁc, UK) at a density of 2 ×
104 cells/well in 300 µL of DMEM supplemented with 10%
FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL
streptomycin. Cells were incubated at 5% CO2, 37 °C and
grown to ~80% conﬂuency (24 h). Cells were washed twice
with PBS, infected with 2 × 1010 phages in PBS/1% BSA in
a total volume of 100 µL, diluted as appropriate by titering
overnight cultures on LB/IPTG/Xgal plates. Cells were
incubated for 2 h at 4 °C. Cells were washed ﬁve times in
cold PBS/1%BSA/0.1% Tween-20 and incubated with
mouse anti-M13 antibody (Abcam, ab9225) at a 1:50
dilution in PBS/1% BSA for 1 h at 4 °C. Bound phage were
detected by incubating cells with Alexa Fluor 488 goat anti-
mouse (Invitrogen, A11017) at a dilution of 1:2000 in PBS/
1% BSA for 45 min at room temperature. Cells were
washed four times in cold PBS/1% BSA and ﬁxed with 4%
PFA for 20 min at room temperature. Cells were washed
with PBS and slides mounted with Prolong Diamond with
DAPI (Invitrogen).
Flow cytometry analysis of TVRTSAE peptide dose-
response and cell binding
SKOV3 were seeded at a density of 1 × 105 cells per well
in a 96-well plate. Cells were washed in 200 µL of wash
buffer (PBS/1% BSA) and incubated with 100 µL of wash
buffer containing either 100 µM, 300 µM or 500 µM
TVRTSAEGGCGG peptide or PBS for 1 h at 4 °C. Cells
were washed and incubated with wash buffer for 1 h at 4 °
C. Cells were ﬁxed in 4% paraformaldehyde for 20 min at
4 °C. A total of 2 × 104 gated events were acquired in
channel FL-4 on a BD Accuri C6 (BD Biosciences, USA)
ﬂow cytometer and data analysed in BD Accuri
C6 software version 1.0.264.21 (Becton Dickinson,
USA). TVRTSAEGGCGG peptide binding was analysed
by ﬂow cytometry relative to PBS control.
Immunoﬂuorescence analysis of TVRTSAE peptide
binding to folic-acid-treated cells
SKOV3 cells were seeded in 8-well Nunc Lab-TekTM II
chamber slides (Thermo-Scientiﬁc, UK) at a density of 2 ×
104 cells/well in 300 µL of DMEM supplemented with 10%
FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL
streptomycin. Cells were incubated in 5% CO2, at 37 °C and
grown to approximately 80% conﬂuency (24 h). Cells were
washed twice with PBS and incubated with either 0.5 mM
folic acid in PBS/1% BSA or complete medium in a total
volume of 300 µL/well for 1 h at 4 °C. Cells were washed
with PBS and incubated with 0.5 mM FITC-labelled
TVRTSAEGGCGG-COOH peptide in PBS/1% BSA in a
total volume of 300 µL/well for 1 h at 4 °C. PBS was used as
a no-peptide control. Cells were washed four times in cold
PBS/1% BSA and ﬁxed with 4% PFA for 20min at room
temperature. Cells were washed with PBS and slides moun-
ted with Prolong Diamond with DAPI (Invitrogen).
Predictive modelling of HAdV-C5 ﬁbre knob protein
containing FRα-binding peptide inserts
The structure of the HAdV-C5 ﬁbre knob containing the
peptide insert was simulated using SWISS-MODEL [26]
and the best available crystal structure of the HAdV-C5
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ﬁbre knob protein as a template (PDB 6HCN) [27]. Struc-
tures were visualised in PyMol [28].
Generation of HAdV vectors
A panel of recombinant HAdV genomes were produced
using HAdV-C5 luciferase-expressing genomes rendered
replication-deﬁcient by deletion of early genes (ΔE1/
ΔE3), with and without the KOI mutation that ablates
binding of adenovirus to CAR, introduced by mutation of
S408E and P409A in the AB loop. FRα-speciﬁc peptides
DWSSWVYRDPQT, CIGNSNTLC and CTVRTSAEC
were inserted in the HI loop of the ﬁbre knob at amino acid
position 542 and the KO1 mutation was introduced by
S408E and P409A in the AB loop. Recombinant HAdV-C5
genomes were generated by homologous recombination in
Escherichia coli strain SW102. Firstly, a SacB selection
cassette was inserted in the HAdV-C5 genome and then
replaced with each of the oligonucleotide sequences repre-
senting each FRα-speciﬁc peptide. DNA extraction and
puriﬁcation was performed by mini-preparation (Qiagen).
Selection cassettes and olignonucleotides containing 100 bp
homology arms were generated by PCR using Expand Hi-Fi
PCR (Roche Applied Science, UK). Conﬁrmation of correct
clone sequences was conﬁrmed by direct DNA sequencing
using a commercial sequencing service.
For generating adenovirus, miniprep DNA was ampliﬁed
in a 10-mL culture for ~8 h and added to a 250-mL culture
overnight. Puriﬁcation was performed using the BacMax
100 kit (Macherey-Nagel, Duren, Germany) and transfected
into T-Rex-293 cells using the Effectene transfection kit
(Qiagen) in T25 tissue culture ﬂasks. When the cytopathic
effect (CPE) was achieved, cells were pelleted and virus
extracted using tetrachloroethylene (Fisher Scientiﬁc,
Loughborough, UK). The initial virus stocks were ampliﬁed
by infecting 5 × T150 conﬂuent T-Rex-293 ﬂasks. Cell
pellets were extracted as before and the virus puriﬁed by
centrifugation using two rounds of caesium chloride (CsCl)
gradient. CsCl was removed from the virus by dialysing
against buffer containing 10% glycerol, 10 mM Tris-HCl
(pH 7.8), 135 mM NaCl, and 1 mM MgCl2·6H2O. Viral
titres were determined using the micro bicinchoninic acid
(BCA) assay (Pierce) with the assumption that 1 μg of
protein equals 4 × 109 viral particles (vp).
Western blotting
The structural integrity of the HAdV-C5 ﬁbre knob proteins
incorporating peptide insertions was assessed by Western
blotting. A total of 1 × 1010 vp/virus stock were run on pre-
made 10% NuPAGE polyacrylamide gels (Invitrogen,
Paisley, UK) by SDS-PAGE and transferred to Hybond-P
nitrocellulose membrane (GE Healthcare Life Sciences,
Little Chalfont, UK) by semidry blotting. Nitrocellulose
membranes were treated with 5 mL of Pierce Miser anti-
body extender (Thermo Scientiﬁc) for 10 min and washed
seven times with distilled water. Membranes were blocked
in 5% milk in Tris-buffered saline containing 0.05%
TWEEN-20 and 0.05% Triton X-100 (TBS-T) overnight at
4 °C. The membrane was incubated in primary anti-
adenovirus ﬁbre antibody 4D2 (Abcam, ab3233) (1:2000)
at 37 °C for 1 h, washed ﬁve times for 5 min in TBS-T and
incubated in anti-mouse IgG-HRP conjugate (1:2000; Insight
Biotechnology Ltd., Wembley, UK) for 1 h at room tem-
perature. After washing a further ﬁve times for 5 min in TBS-
T, the membrane was incubated for a maximum of 10min in
Super Signal West Pico Chemiluminescent substrate
(Thermo Scientiﬁc) and analysed on GelDoc autoChemi
camera (Ultra-Violet Products Ltd., Cambridge, UK).
In vitro adenovirus-mediated cell transduction
In brief, cells were seeded at a density of 2 × 104 cells/well
in a 96-well plate. After 24 h, cells were infected with
luciferase-expressing HAdV vectors at a dose of 5000 vp/
cell in a total volume of 100 µL of serum-free medium and
incubated at 5% CO2, 37 °C for 3 h. The medium was
removed and replaced with 200 μL of complete medium
(RPMI 1640 medium supplemented with 10% (v/v) FCS,
100 U/mL penicillin, 100 µg/mL streptomycin) and cultured
for an additional 45 h. Cells were lysed in 1X Cell Culture
Lysis Buffer (Promega, UK) and frozen at −70 °C. The
cells were thawed and 20 µL of cells were mixed with
100 µL of luciferase assay reagent in a white 96-well plate.
Luciferase activity in relative light units (RLU) was mea-
sured immediately using a multimode plate reader
(FLUOstar Omega, BMG Labtech, Aylesbury, UK). Sam-
ples were normalised for total protein content, as measured
by BCA assay in RLU/mg protein. A total of 2 × 104 gated
events were acquired in channel FL-1 on a BD Accuri C6
using the plate reader as described above.
Adenovirus labelling and confocal microscopy
Adenovirus particles were incubated with a 20-fold excess
of Alexa Fluor 488-TFP (Molecular Probes) for 1.5 h at
room temperature in 10% glycerol/100 nM NaHCO3/PBS
buffer, pH 7.2. Unbound dye was removed from the
labelled virus using two Zeba Spin desalting columns
(Pierce) with exchange buffer 10% glycerol in PBS buffer.
SKOV3 cells were seeded in 24-well plates on coverslips
at a density of 2 × 104 cells/well. Two days later, labelled
adenoviruses were added to the cells (250,000 vp/cell) in
serum-free medium and incubated on ice for 45min. Cells
were then transferred to 37 °C and after 30 or 60min were
ﬁxed (2% paraformaldehyde in PBS for 12min at room
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temperature), permeabilised (0.1% Triton X-100 in PBS for
2 min at room temperature) and incubated with Alexa Fluor
555 Phalloidin (Thermo Fisher). Coverslips were mounted
using Fluoromount G (Southern Biotech) containing DAPI
for labelling the nuclei. Leica TCS SP8 microscope with 63×
objective was used for imaging. The images were analysed
using LAS X (Leica Microsystems, Germany) software and
they are showing maximum projections of confocal stacks.
Statistical analyses
Data are presented as experiments performed in triplicate or
quadruplicate as indicated in the relevant ﬁgure legends. All
analyses and graphs were created in GraphPad Prism ver-
sion 6.03 (GraphPad Software Inc., La Jolla, CA, USA).
P values ≤ 0.05 were considered statistically signiﬁcant.
Results
Identiﬁcation of FRα-binding peptides
FRα expression on SKOV3 cells was ﬁrst conﬁrmed by
ﬂow cytometry (Fig. 1a) to ensure this was an appropriate
cell line for our biopanning strategy. The Ph.D.−7 (7-mer),
Ph.D.−C7C (7-mer) and Ph.D.−12 (12-mer) phage-display
libraries displaying random peptides on the coat protein
were incubated on SKOV3 cells and eluted with folic acid
(100 µg/mL) to elute FRα-speciﬁc binding peptides for each
library. A total of six rounds of biopanning was performed.
Phage clones were randomly picked and characterised by
DNA sequencing. Consensus sequences iterated for the 12-
mer and 7-mer (Ph.D.−C7C) libraries are shown in Table 1.
The linear 7-mer library (Ph.D.−7) failed to identify any
consensus sequence. After each panning round, phages
were titred to determine phage recovery. Homogenous
solutions of phage-presenting peptides of interest were used
in binding studies on SKOV3 cells (Fig. 1b) and fold-
change relative to insert-less phage was calculated (Fig. 1c).
CTVRTSAEC phage showed the highest fold increase in
recovery on SKOV3 cells followed by CIGNSNTLC in
comparison to the other phage clones. To further evaluate
the binding of phage clones expressing the lead
peptide sequences CTVRTSAEC, CIGNSNTLC and
DWSSWVYRDPQT to SKOV3 cells in vitro, homogenous
phage solutions were incubated on SKOV3 cells, and their
binding detected using and anti-M13 antibody. Immuno-
cytochemical analysis demonstrated that phage displaying
CB
IgG
FR
A
CTVRTSAEC
CIGNSNTLC
DWSSWVYRDPQT
insert-less
DAPI an-M13 mergedD
*
*
Fig. 1 Identiﬁcation and characterisation of FRα binding oligo-
peptides from phage display libraries. a Characterisation of FRα
expression on SKOV3 cells. b Phage peptide recovery from SKOV3
cells eluted with folic acid. Cell binding of homogeneous selected
phage clones recovered from SKOV3 cells eluted with folic acid,
c fold change relative to insert-less phage. Bars represent the mean ±
S.D. #P ≤ 0.05 versus DRLADGV (non-consensus) control peptide.
*P ≤ 0.05 versus insert-less control peptide. d Phage clones bind
SKOV3 cells in vitro. 7-mer cyclic phage peptides (CTVRTSAEC,
CIGNSNTLC) and 12-mer linear peptides (DWSSWVYRDPQT) bind
to SKOV3 cells. Cells were infected with 2 × 1010 pfu of phages at
4 °C and detected by anti-M13 antibody. An empty (insert-less) phage
clone was used as a control.
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CIGNSNTLC, DWSSWVYRDPQT and, in particular,
CTVRTSAEC were better able to bind to SKOV3 cells
compared to control phage (Fig. 1d).
Evaluation of TVRTSAE-binding SKOV3 cells
To determine whether the TVRTSAE peptide binds SKOV3
cells outside of the constraints of a phage virion, Alexa
Fluor 647-labelled peptide (TVRTSAEGGCGG) was
incubated at escalating doses of peptide; 100 µM, 300 µM
and 500 µM and cell binding determined by ﬂow cytometry
(Fig. 2a). The data show a corresponding increase in
SKOV3 cell binding with increasing peptide dose. No
peptide (PBS) was used as a control. To conﬁrm that
TVRTSAE peptide binds SKOV3 cells via the FRα, FITC-
conjugated peptide (TVRTSAEGGCGG-COOH) (500 µM)
was tested for its ability to bind SKOV3 cells by competi-
tive inhibition with pre-treatment of cells with folic acid
(0.45 µM), the native ligand for FRα. Peptide binding was
prevented when cells were pre-treated with folic acid as
determined by immunocytochemistry (Fig. 2b).
Predictive structural modelling of HAdV-C5 ﬁbre
knob protein containing FRα-binding oligopeptides
To assess the possibility that genetic incorporation of FRα-
binding oligopeptides into the HAdV-C5 ﬁbre knob pro-
tein might cause signiﬁcant structural alterations to the
protein, we performed modelling analysis of the predicted
structures (Fig. 3). The structure of the HAdV-C5 knob
protein (based on PDB 6HCN) containing each peptide
insert was simulated using SWISS-MODEL, and the
resultant structures visualised using PyMol. Each of the
structures was modelled within the wild-type HAdV-C5
ﬁbre knob protein as well in a CAR-binding ablating
mutant, containing two mutations, S408E and P409A,
within the ﬁbre knob AB loop. The resultant structures
demonstrated that the peptide insert was presented in a
distal manner, extending away from the ﬁbre knob protein,
in a manner that ought to be favourable for receptor
interactions. Peptide insertions were shown to be distant
from the putative CAR-binding site within the ﬁbre knob
protein. The predicted structures therefore gave conﬁdence
that the resultant vectors should be viable and present
FRα-interacting oligopeptides in a manner compatible
with receptor engagement.
Genetic engineering of HAdV-C5 vectors to
incorporate FRα-speciﬁc peptides within the ﬁbre
knob protein
We developed a panel of retargeted HAdV vectors pre-
senting FRα peptide-binding sequences in the adenoviral
ﬁbre knob as a retargeting approach for selective targeting
to FRα (Table 2). Retargeted HAdVs were produced by
AdZ homologous recombineering as described previously
[29]. The HAdV-C5 parental vector was rendered
replication-deﬁcient by deletion of E1 and E3 genes (ΔE1/
ΔE3). Peptide sequences were incorporated into the
HAdV-C5 genome within the HI loop of the HAdV-C5
ﬁbre knob domain after Thr541 (Table 2) since this region
is permissible for incorporation of peptides [30]. CAR-
binding ablated HAdV-C5 vectors were developed by
incorporation of point mutations S408E and P409A (KO1)
within the AB loop of the ﬁbre knob domain (Table 2).
Such KO1 mutations preclude interactions between ade-
novirus and the native receptor for cell entry CAR [31].
Direct sequencing of HAdV genomes within the region of
homologous recombination and ﬂanking regions con-
ﬁrmed correct adenoviral genomic sequences (Fig. 4a).
The structural integrity of retargeted HAdV ﬁbre knobs
incorporating peptide insertions was evaluated by Western
blot (Fig. 4b). All retargeted HAdV ﬁbre knobs show a
distinct band at 60 kDa, consistent with intact HAdV ﬁbre
knobs.
Evaluation of FRα retargeted HAdV vector
transduction
We tested the efﬁciency of our panel of HAdV vectors in
transducing CARlow/FRα-positive SKOV3 cells. Unfortu-
nately, our data demonstrated that the incorporation of FRα-
binding oligopeptides did not signiﬁcantly enhance trans-
duction via FRα in comparison with the parental HAdV-5
vector (Fig. 5), regardless of the CAR-binding status of the
parental virus. Unmodiﬁed, control HAdV5 showed luci-
ferase expression of 9.8 × 104 RLU/mg protein, viruses
HAdV-C5.DWSS, HAdV-C5.IGN and HAdV-C5.TVR
achieved levels of 4.36 × 104, 4.59 × 104 and 4.68 × 104
RLU/mg protein, respectively. Similarly, the HAdV-C5.
KO1 control virus showed luciferase expression of 2.87 ×
104 RLU/mg protein, whereas viruses HAdV-C5.KO1.
DWSS, HAdV-C5.KO1.IGN and HAdV-C5.KO1.TVR
achieved levels of 3.95 × 104, 3.1 × 104 and 1.36 × 104
RLU/mg protein, respectively.
Table 1 Frequency of phage peptide sequences derived from SKOV3
cell biopanning using the Ph.D.−12 and Ph.D.−C7C phage-display
library.
Phage library Frequency Frequency (%) Amino acid sequence
12-mer 6 10 DWSSWVYRDPQT
C7C 5 9 CIGNSNTLC
C7C 4 7 CTVRTSADC
12-mer 3 5 SGVYKVAYDWQH
C7C 2 4 CTVRTSAEC
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Evaluation of cell binding and trafﬁcking of FRα
retargeted adenoviral vectors
To assess whether the limited transduction ability observed
using FRα retargeted adenoviral vectors was due to defects
in cellular binding to FRα or impaired intracellular traf-
ﬁcking pathways of virions post-entry, we performed con-
focal imaging studies using ﬂuorescently labelled HAdV-
C5-based vectors. We restricted this analysis to the purely
CAR-engaging HAdV-C5 vectors, and the fully FRα
retargeted vector HAdV-C5.KO1.TVR. Confocal imaging
of viral attachment and trafﬁcking demonstrated that the
FRα retargeted HAdV.KO1.TVR vector can attach and
internalise into SKOV-3 cells more efﬁciently than the
CAR-engaging HAdV-C5 vector (Fig. 6). This is likely due
to the relatively low expression levels of CAR on SKOV-3
cells (Fig. 5a) compared to high-level expression of FRα
(Fig. 1a). Internalised HAdV-C5 was observed to trafﬁc
efﬁciently to the microtubule-organising centre (MTOC),
accumulating within the perinuclear region by 60 min.
Conversely, FRα internalised HAdV-C5.KO1.TVR
appeared to be unable to trafﬁc efﬁciently to the MTOC or
the perinuclear region. Taken together, these data indicate
that whilst FRα retargeted viral vectors appear compatible
No pepde TVRTSAE (100 μm) TVRTSAE (300 μM) TVRTSAE (500 μM)A
B
DAPI FITC-TVRTSAE merged
- folic acid
+ folic acid
Fig. 2 Evaluation and competitive inhibition of TVRTSAE peptide
binding to FRα on SKOV3 cells. a Synthesised TVRTSAE peptide
binding to SKOV3 cells increases with escalating peptide concentra-
tion. SKOV3 cells were incubated with increasing peptides con-
centration (100, 300 or 500 µM) for 1 h at 4 °C and analysed by ﬂow
cytometry. PBS was used as a no-peptide control. b FITC-TVRTSAE
peptide binds to SKOV3 cells via the FRα. Representative
immunoﬂuorescence images show FITC-TVRTSAE peptide binding
to SKOV3 cells. FITC-labelled TVRTSAEGGCGG-COOH peptide
(0.5 mM) was incubated on SKOV3 cells in PBS/1% BSA for 1 h at
4 °C (upper panel). Cells treated with folic acid (0.5 mM) in PBS/1%
BSA were incubated for 1 h at 4 °C prior to treatment with peptide
(lower panel).
S. L. Hulin-Curtis et al.
with cell binding and uptake, entry via the FRα is not
compatible with efﬁcient viral trafﬁcking post-entry,
resulting in inefﬁcient delivery of virions to the nuclear pore
complex (NPC).
Discussion
HAdV-C5 is the most commonly used HAdV vector for
gene and virotherapy applications; however, the clinical
utility of HAdV-C5 is severely hampered by a lack of
tumour speciﬁcity, neutralisation by pre-existing anti-
bodies and interactions with blood coagulation factors
that sequester adenovirus to the liver [24, 32–40]. To
improve the speciﬁcity of HAdV vectors for ovarian
cancer cells, we developed a panel of vectors retargeted to
the FRα by genetically incorporating peptides identiﬁed
to bind FRα from phage biopanning. Peptides were
genetically incorporated in a permissive region of the
HAdV-C5 ﬁbre knob HI loop, the capsid protein involved
in cell binding. Phage display represents a powerful
technique for determining cancer-targeting ligands for
various targets in cancer cells [41].
We identiﬁed three phage peptides DWSSWVYRDPQT,
CIGNSNTLC and CTVRTSAEC that showed binding
speciﬁcity to SKOV3 cells in vitro. Phage recovery of
from SKOV3 cells identiﬁed CTVRTSAEC as the lead
peptide. We show that synthetic TVRTSAE peptide binds
SKOV3 cells in a dose-dependent manner and binds via
the FRα since binding was inhibited when cells were pre-
treated with the FRα ligand folic acid. In similar studies,
peptide MHTAPGWGYRLS was identiﬁed as a FRα-
speciﬁc peptide using the same Ph.D–12 phage-display
library for biopanning SKOV3 cells [42]. Peptide
SWQIGGN was found to target HO8910 ovarian cancer
cells in vitro, inhibiting cell viability, migration invasion
No pepde DWSSWVYRDPQT CIGNSNTLC CTVRTSAEC
Trimer
Monomer
Fig. 3 Predictive modelling of HAdV-C5 ﬁbre knob proteins con-
taining FRα-binding oligopeptides. Mutated residues involved in
CAR binding (KO1 mutation, 408S, 409P, blue sticks) are distant from
the insert site (green surface) in the adenovirus 5 ﬁbre knob trimer (a)
residing in the lateral portion of the monomeric unit (b). The trimers
containing peptides (white sticks, red surface) DWSSWVYRDPQT
(c), CIGNSNTLC (d) and CTVRTSAEC (e) are highlighted (red)
within the trimeric ﬁbre knob protein. In the monomeric unit of the
ﬁbre knob, peptides (red cartoon) DWSSWVYRDPQT (f),
CIGNSNTLC (g) and CTVRTSAEC (h) are visualised and appear to
possess different conﬁrmations.
Table 2 Amino acid position of
(peptide) DNA oligonucleotides
inserted into the HI loop of the
Ad5 and Ad5.KO1 ﬁbre knobs
by AdZ homologous
recombineering.
AB loop HI loop
Amino acid (ﬁbre knob) 408 409 540 541 543
Ad5 S P E T - - - - - - - - - - - - G
Ad5 DWSSWVYRDPQT S P E T DWSSWVYRDPQT G
Ad5 CIGNSNTLC S P E T CIGNSNTLC G
Ad5 CTVRTSAEC S P E T CTVRTSAEC G
Ad5.KO1 E A E T - - - - - - - - - - - - G
Ad5.KO1 DWSSWVYRDPQT E A E T DWSSWVYRDPQT G
Ad5.KO1 CIGNSNTLC E A E T CIGNSNTLC G
Ad5.KO1 CTVRTSAEC E A E T CTVRTSAEC G
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and cell adhesion. SWQIGGN peptide treated HO8910
cells injected into BALBC/c nude mice showed reduced
volume of ascites and tumour nodule formation in vivo in
comparison to control peptide-treated cells [43]. Peptide
NPMIRRQ has also been reported as a speciﬁc binder to
HO8910 ovarian cancer cells in vitro [44] demonstrating
plasticity in the sequence of binding peptides for target
cells. To the best of our knowledge, our study is the
ﬁrst to report identiﬁcation of CTVRTSAEC peptide
from phage display biopanning. A similar peptide
CTVRTSADC differing by a substitution of glutamic to
aspartic acid (both charged amino acids) speciﬁcally tar-
gets prostate cancer cells in vivo [45]. The same Ph.
D–C7C phage library as in our study was used for bio-
panning extradomain-B ﬁbronectin (EDB-ﬁbronectin), a
marker of epithelial–mesenchymal transition (EMT) in
prostate cancer. Cy5-labelled CTVRTSADC demonstrated
increased binding to upregulated EDB-ﬁbronectin in
prostate cancer (PC3) cells in vitro and in vivo following
intravenous injection in nude mice bearing PC3-GFP
tumour xenografts. Interestingly, TVRTSAD and a linear
IGNSNTL version of the cyclised CIGNSNTLC peptide
discovered herein were reported to target human lung
cancer cells in an in vivo mouse model of biopanning [46].
Mice bearing an A549-derived xenograft tumour were
intravenously injected with the Ph.D.−C7C phage library
into the tail vein. Four rounds of biopanning were per-
formed and phage clones determined from resected
tumour. Both TVRTSAD and IGNSNTL peptides were
amongst the most commonly occurring phage peptides,
however, when peptides were labelled with Cy5.5 and
injected into the tail vein of the same mouse model.
Although both peptides demonstrated speciﬁc targeting to
the A549 xenograft tumour, they failed to accumulate in
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Fig. 4 Production and validation of recombinant HAdV-C5 vec-
tors containing FRα-binding oligopeptides within the ﬁbre knob
protein. a Direct sequencing of recombinant HAdV-C5 and HAdV-
C5.KO1 vectors generated, conﬁrming successful peptide integration.
Translated nucleotide to amino acid sequences are shown in italics.
b Representative western blot conﬁrming the structural integrity of
recombinant Ad ﬁbre knobs using a mouse monoclonal antibody
[4D2] speciﬁc to adenovirus ﬁbre monomer and trimer. For simplicity,
HAdV-C5 is abbreviated to Ad5 in the ﬁgure.
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the tumour as abundantly as other candidate peptides and
hence were not studied further.
DWSSWVYRDPQT peptide identiﬁed in this study
reportedly targets colon cancer cells in vitro with in silico
analysis suggesting the peptide targets glypican-3 (a heparin
sulphate proteoglycan (HSPG)) [47]. We checked all pep-
tides identiﬁed in this study with SAROTUP (Scanner and
Reporter of Target Un-related peptides). The
DWSSWVYRDPQT peptide is considered a potentially
false-positive peptide where the sequence WXXW binds
plastic with no actual afﬁnity towards the target but rather
the (plastic surface) solid phase [48], although data from
others [47] would suggest otherwise.
We developed a panel of retargeted HAdV vectors by
genetic incorporation of each of the phage peptides into
the HI loop of the adenoviral ﬁbre knob, the capsid protein
that interacts with the native adenoviral receptor, CAR,
and considered an appropriate location for targeting
moieties [49, 50]. We evaluated the transduction cap-
abilities of each retargeted HAdV-C5 vector with and
without a KO1 mutational background that precludes
interactions of adenovirus with the native CAR. Our data
show that all retargeted HAdV vectors, regardless of
whether CAR binding or not, poorly transduced SKOV3
cells in comparison to the parental HAdV-C5 vector except
for HAdV-C5.KO1.DWSS that marginally increased trans-
duction in single experiments (data not shown) but not
overall when repeated in a total of four experiments. These
data are in concordance with a similar study that geneti-
cally incorporated known tumour targeting peptides iso-
lated from in vivo phage-display biopanning; RGD, NGR
and ASL into the HI loop of HAdV-5. HAdV vectors
retargeted by incorporating peptides in the HI loop and de-
targeted with CAR and HSPG mutations showed minimal
improvements in transduction of a number of cell types
expressing low CAR and in some cases, attenuated ade-
noviral transduction in comparison to de-targeted vectors
with no peptide insertion [51]. Other studies show that
incorporation of the RGD motif into the HI loop can
reduce native CAR binding [52]. One possible explanation
for their ﬁndings is the conformational structure of the
presented peptide. Transduction of HAdV vectors pre-
senting the cyclised NGR peptide (ﬂanked by cysteine
residues and disulphide bond formation conﬁrming a
cyclic structure) in the HI loop retargets adenovirus to
APN, whereas HAdV vectors containing linear NGR
peptide retargets adenovirus to aminopeptidase N (albeit
with a lower afﬁnity) [23]. This is one possible explana-
tion as to why elucidated peptides may fail to target efﬁ-
ciently outside of the context of the phage virion from
which the phage peptide was selected during biopanning.
An alternative explanation is that the presentation of the
peptide within the ﬁbre knob protein may be compatible
with receptor engagement at the cell surface, but the route
of cell entry is not compatible with efﬁcient post-entry
trafﬁcking of the internalised virion. Interestingly, our
confocal analysis of labelled HAdV-C5 and HAdV-C5.
KO1.TVR particles appear to demonstrate that the latter is
the case here. FRα retargeted vectors generated in this
study were clearly compatible with efﬁcient FRα-mediated
cell attachment and internalisation, but were defective in
intracellular trafﬁcking post entry, resulting in a poor
overall transduction efﬁciency.
In summary, we demonstrate that TVRTSAE peptide
binds FRα on SKOV3 cells in vitro and may represent a
potential platform for peptide conjugated drug or gene
delivery via liposomes or other viral or non-viral gene
transfer applications. In the context of retargeted HAdVs,
our panel of peptides failed to enhance FRα-mediated
transduction in SKOV3 cells due to defects in intracellular
0
5×104
1×105
1.5×105
IgG
CAR
A
B
Fig. 5 In vitro SKOV3 cell transduction of FRα retargeted HAdV-
C5 incorporating peptide oligonucleotides in the HI loop of the
ﬁbre knob. a SKOV3 cell receptor expression of CAR as determined
by ﬂow cytometry. b SKOV3 cells were transduced with luciferase
expressing HAdV-C5, HAdV-C5.DWSS, HAdV-C5.IGN, HAdV-C5.
TVR, HAdV-C5.KO1, HAdV-C5.KO1 DWSS, HAdV-C5.KO1.IGN
or HAdV-C5.KO1.TVR at 5 × 103 vp/cell in the presence of serum-
free medium. Cell transduction was measured by luciferase activity
48 h post-infection and normalised for protein content by bicincho-
ninic acid assay (RLU/mg). Data are represented as the mean RLU/mg
protein ± S.D. for each triplicate sample (n= 4 experiments). For
simplicity, HAdV-C5 is abbreviated to Ad5 in the ﬁgure.
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trafﬁcking. Further studies to characterise the reasons for
the defective trafﬁcking of FRα-retargeted HAdV-based
vectors are warranted.
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